Stock DNA
Pharmaceuticals & Biotechnology
SEK 512 Million ()
NA (Loss Making)
NA
0.00%
-5.60
1,226.67%
-141.48
Revenue and Profits:
Net Sales:
(Quarterly Results - Jun 2025)
Net Profit:
-13 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-11.46%
0%
-11.46%
6 Months
-11.03%
0%
-11.03%
1 Year
-10.6%
0%
-10.6%
2 Years
-41.67%
0%
-41.67%
3 Years
-19.35%
0%
-19.35%
4 Years
-54.76%
0%
-54.76%
5 Years
0%
0%
0.0%
FluoGuide A/S for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
0
EBIT Growth (5y)
-206.39%
EBIT to Interest (avg)
-38.65
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-0.60
Sales to Capital Employed (avg)
0
Tax Ratio
15.96%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
0
ROE (avg)
0
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
68.14
EV to EBIT
-11.93
EV to EBITDA
-12.10
EV to Capital Employed
47.42
EV to Sales
NA
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
-397.47%
ROE (Latest)
-498.10%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bearish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Bearish
Mildly Bearish
Moving Averages
Mildly Bullish (Daily)
KST
Bullish
Mildly Bullish
Dow Theory
No Trend
Mildly Bearish
OBV
No Trend
Mildly Bullish
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Quarterly Results Snapshot (Consolidated) - Jun'25 - YoY
Jun'25
Jun'24
Change(%)
Net Sales
0.00
0.00
Operating Profit (PBDIT) excl Other Income
-14.30
-13.90
-2.88%
Interest
1.30
0.90
44.44%
Exceptional Items
0.00
0.00
Consolidate Net Profit
-13.10
-11.10
-18.02%
Operating Profit Margin (Excl OI)
0.00%
0.00%
NA
USD in Million.
Net Sales
YoY Growth in quarter ended Jun 2025 is 0.00% vs 0.00% in Jun 2024
Consolidated Net Profit
YoY Growth in quarter ended Jun 2025 is -18.02% vs -0.91% in Jun 2024
Annual Results Snapshot (Consolidated) - Dec'24
Dec'24
Dec'23
Change(%)
Net Sales
0.00
0.00
Operating Profit (PBDIT) excl Other Income
-50.60
-67.90
25.48%
Interest
2.20
2.60
-15.38%
Exceptional Items
0.00
2.60
-100.00%
Consolidate Net Profit
-44.40
-59.10
24.87%
Operating Profit Margin (Excl OI)
0.00%
0.00%
NA
USD in Million.
Net Sales
YoY Growth in year ended Dec 2024 is 0.00% vs 0.00% in Dec 2023
Consolidated Net Profit
YoY Growth in year ended Dec 2024 is 24.87% vs -51.15% in Dec 2023
About FluoGuide A/S 
FluoGuide A/S
Pharmaceuticals & Biotechnology
FluoGuide A/S is a Denmark-based provider of solutions for maximizing surgical outcome through intelligent targeting. The Company develops surgical solutions, which expected to reduce Cancer pain for the patient and increases the possibility of recovering as well as reducing costs for the health care system. The first product is the compound FG001, which lights up the cancer and its invasive growth into the surrounding tissue.
Company Coordinates 
Company Details
Ole Maaloees Vej 3, Copenhagen N , COPENHAGEN None : 2200
Registrar Details






